The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer

Colorectal cancer (CRC) has the second highest mortality rate among all cancers worldwide. Surgery, chemotherapy, radiotherapy, molecular targeting and other treatment methods have significantly prolonged the survival of patients with CRC. Recently, the emergence of tumor immunotherapy represented b...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 792691
Main Authors Chen, Yaping, Zheng, Xiao, Wu, Changping
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 02.12.2021
Subjects
Angiogenesis Inhibitors - therapeutic use
Animals
Antineoplastic Agents, Immunological - therapeutic use
bevacizumab
colorectal cancer
Colorectal Neoplasms - immunology
Colorectal Neoplasms - therapy
Humans
Immune Checkpoint Inhibitors - therapeutic use
immune microenvironment
Immunology
immunotherapy
Immunotherapy - methods
PD-1
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Tumor Microenvironment
Vascular Endothelial Growth Factor A - antagonists & inhibitors
bevacizumab
colorectal cancer
immune microenvironment
PD-1
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Colorectal cancer (CRC) has the second highest mortality rate among all cancers worldwide. Surgery, chemotherapy, radiotherapy, molecular targeting and other treatment methods have significantly prolonged the survival of patients with CRC. Recently, the emergence of tumor immunotherapy represented by immune checkpoint inhibitors (ICIs) has brought new immunotherapy options for the treatment of advanced CRC. As the efficacy of ICIs is closely related to the tumor immune microenvironment (TME), it is necessary to clarify the relationship between the immune microenvironment of CRC and the efficacy of immunotherapy to ensure that the appropriate drugs are selected. We herein review the latest research progress in the immune microenvironment and strategies related to immunotherapy for CRC. We hope that this review helps in the selection of appropriate treatment strategies for CRC patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Elena Ciaglia, University of Salerno, Italy
Reviewed by: Valentina Lopardo, University of Salerno, Italy; Biao Yang, Sichuan University, China; José Medina-Echeverz, Affimed Therapeutics, Germany
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.792691